Sinovac is also undertaking phase 3 trials in Turkey and Indonesia as well as Brazil; data from these are assessing efficacy and will be the real litmus test for this vaccine. Please see our Privacy Notice for details of your data protection rights.
Crucially, no adverse health problems were reported during the trials.
Oxford University and AstraZeneca Plc's Covid-19 antibody shot has created a "powerful immune reaction" in older candidates over 60 years old and is secure, as indicated by another study from mid-stage trials uncovered this Wednesday.
Almost one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country's emergency use programme, the firm said late on Wednesday. "If so, it will give an opportunity for India regulator also (to consider such an option)", Dr Vinod Paul, member Niti Aayog and chairman of the National Expert Group on Vaccine Administration for COVID-19, has said.
A senior doctor has warned that covid-19 will remain a serious threat if too many people shun any new vaccine.
"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure". In recent months, China granted companies the authorization for the urgent use of vaccines.
The authors note some limitations to their study, including that the participants in the oldest age group had an average age of 73-74 and few underlying health conditions, so they may not be representative of the general older population, including those living in residential care settings or aged over 80.
This vaccine developed by Sinopharm has already completed the phase three of trials after completion of work carried out in ten countries, including the United Arab Emirates, Bahrain, Egypt, Jordan, Peru and Argentina.
While high-risk groups will be the first vaccinated, the U.S. government hopes that there will be enough vaccines by April 2021 to offer it to the broader population and provide high coverage by the summer.
"It is with great pride and joy, and even a little relief, that I can say that our request for emergency use authorization for our Covid-19 vaccine is now in the FDA's hands", said Pfizer chief executive Albert Bourla.